CHW Home Visit + Wearable Tech for Dementia Caregivers
What You Need to Know Before You Apply
What is the purpose of this trial?
The proposed study will test a 3-month, community health worker (CHW) delivered home visit, culturally and language-appropriate intervention for ethnic and underserved dementia family caregivers of persons with dementia (PWD) using wearable technology for real time monitoring of caregivers' stress and sleep. The CHW delivered home visit intervention includes stress reduction techniques by mindful deep breathing and compassionate support/listening and caregiving education to improve caregiver's health, wellbeing, and positive interactions with the PWD. This dementia caregiver study using wearable technology has the potential to significantly lessen health disparities in dementia care, assisting underserved ethnic dementia caregivers in self-management and increasing their quality of life.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It mainly focuses on the use of wearable technology and does not mention medication changes.
Is the CHW Home Visit + Wearable Tech for Dementia Caregivers generally safe for humans?
The research articles provided do not contain specific safety data for the CHW Home Visit + Wearable Tech for Dementia Caregivers intervention. They focus on the roles and effectiveness of community health workers in various contexts, but do not address safety concerns related to this specific intervention.12345
How is the CHW Home Visit Intervention treatment different from other treatments for dementia caregivers?
The CHW Home Visit Intervention is unique because it involves community health workers visiting caregivers at home, providing personalized support and guidance, which is not a standard approach in dementia care. This method leverages the community health workers' ability to connect with caregivers in their own environment, potentially improving caregiver well-being and reducing stress.13467
What data supports the effectiveness of the treatment Attention Control Group with WIoT Technology, Wearable Technology Intervention, WIoT Technology Intervention, Attention Control Group with Wearable Technology, Community Health Worker (CHW) Home Visit Intervention, Community Health Worker Home Visit Intervention, CHW Intervention, Dementia Family Caregiver Support Program, Usual Care, Standard Care, Conventional Care?
Research shows that Community Health Workers (CHWs) can significantly improve health outcomes by helping patients navigate the healthcare system, providing emotional support, and offering hands-on education, especially for underserved populations. This suggests that CHW interventions, as part of the treatment, could be effective in supporting dementia caregivers.158910
Who Is on the Research Team?
Jung-Ah Lee, PhD
Principal Investigator
Associate Professor
Are You a Good Fit for This Trial?
This study is for family caregivers of people with dementia who are primary care providers. Participants must be Korean, Vietnamese, Latino/Hispanic, or non-Hispanic Whites and speak English, Spanish, Vietnamese, or Korean. They should agree to wear a smartwatch during the day and a smartring at night for 3 months.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Community health workers deliver a 3-month home visit intervention with stress reduction techniques, caregiving education, and wearable technology monitoring.
Follow-up
Participants are monitored for outcomes such as caregiver burden, depression, and self-efficacy at baseline, 3 months, and 6 months.
Extension
Participants in the Usual Care group receive wearable devices after 6 months for continued monitoring.
What Are the Treatments Tested in This Trial?
Interventions
- Attention Control Group with WIoT Technology
- Community Health Worker (CHW) Home Visit Intervention
- Usual Care
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, Irvine
Lead Sponsor
National Institute on Aging (NIA)
Collaborator